by immunoblot and densitometric analysis of the ratio of phospho-AKT to total AKT ( Figures 1B and 1D ). Densiis an atrophy-related gene ("atrogene") that is induced in many, perhaps all, types of muscle atrophy (Lecker et tometric analysis revealed that the ratio of phospho-AKT to total AKT fell consistently when atrogin-1 al., 2004). These atrophy-related genes (formerly termed "atrogins") are here called "atrogenes" to prevent confumRNA increased. A reduction in AKT activity would be expected to lead sion with the ubiquitin-ligase, atrogin-1.
We have used two simple in vitro models of muscle to decreased phosphorylation of Foxo1, 3, and Foxo4 and in fact, the levels of phosphorylated Foxo1 and atrophy, cell starvation, and treatment with the synthetic glucocorticoid, dexamethasone, to identify the down-3 decreased in the starved and Dex-treated cultures. Forkhead factors shuttle between the nucleus and cytostream targets of the IGF1/PI3K/AKT pathway that are important for the induction of atrogin-1 and the developplasm and when phosphorylated, are sequestered in the cytoplasm in association with 14-3-3 proteins. We ment of muscle wasting. We demonstrate that IGF-1 acts through AKT and Foxo to suppress atrogin-1 tranmeasured the amount of Foxo in nuclear extracts of myotubes after starvation. A marked increase in nuclear scription, and that the mTOR/S6K, GSK, and NFB pathways are not important in regulating atrogin-1 expresFoxo1 and Foxo3 content was seen after starvation for 2 hr ( Figure 1E , left image). To test if these nuclear sion. Further studies show that Foxo3 activation also causes transcription of the atrogin-1 promoter and a Foxo species had DNA binding activity, we used an electrophoretic mobility shift assay ( Figure 1E , right imdramatic decrease in fiber size. Our surprising discovery of the key role of Foxo in triggering the atrophy program age). Factors in the nuclear extract from starved (but not control) myotubes bound to an oligonucleotide conshould lay the basis not only for further understanding of the mechanisms of muscle wasting in diverse distaining a known forkhead binding site. A 100-fold molar excess of this unlabeled oligonucleotide (competitor) eases, but also for developing novel therapies for these debilitating conditions. prevented formation of the complex, but an unrelated oligonucleotide (non competitor) containing an SP1 binding site did not. to Foxo3. A detailed analysis of that short sequence Foxo3 as was the atrogin-1 promoter. Furthermore, the revealed two potential forkhead binding sites, one lofibers overexpressing Foxo3 also showed increased cated just past the transcription start site (Foxo 1 , ϩ2), atrogin-1 mRNA levels as detected by in situ hybridizaand a second partially overlapping the putative TATA tion ( Figure 5D ). box at Ϫ94 relative to the transcription start site (Foxo 2 ) To test whether Foxo also induces atrogin-1 in atro-( Figure 6C ). The ability of forkhead to bind to these sites phying muscle during fasting, we expressed an RNAi was tested in an electrophoretic mobility shift assay containing a region that blocks the function of both using a purified forkhead fusion protein ( Figure 6D ).
Foxo1 and Foxo3. Electroporation of the RNAi com-
FoxoGST, bound to a known forkhead site from the pletely prevented the induction of the atrogin-1 pro-IGFBP1 promoter. A 100-fold molar excess of unlabeled moter in these muscles 24 hr after food deprivation (Fig-IGFBP1 oligonucleotide 
prevented formation of the ure 5E). In myotubes, this RNAi construct reduced Foxo1
FoxoGST-IGFBP1 complex. Formation of this complex and 3 levels by more than 50%. By contrast, a control was also markedly reduced by an unlabeled oligonucleRNAi (against GFP) did not affect the activation of the otide containing one of the putative forkhead binding atrogin-1 promoter. In addition, RNAi against unique sites in the atrogin-1 promoter, ATAAATA (AT Foxo 1). n. AKT, the c.a. AKT, the c.a. GSK3, d.n. SK3, c.a. NIK, c.a.  IB, human Foxo3 (FOXO3A), c.a. FOXO3A, d.n. FOXO3A, control ered statistically significant.
